Broad-Spectrum Antiviral (BSA) Drug
(Redirected from broad-spectrum antiviral)
Jump to navigation
Jump to search
A Broad-Spectrum Antiviral (BSA) Drug is an Antiviral Drug that targets and inhibits the replication and development of a broad range of viral pathogens.
- Example(s):
- Remdesivir.
- …
- Counter-Example(s):
- See: COVID-19 Drug Repurposing Research, Antiviral Drug, Viral Life Cycle, Viral Disease, Viral Protein, Reverse Transcriptase, Lopinavir/Ritonavir.
References
2020
- (Wikipedia, 2020) ⇒ https://en.wikipedia.org/wiki/broad-spectrum_antiviral_drug Retrieved:2020-5-1.
- Broad-spectrum antiviral drugs (BSA) are a class of antiviral drugs, which target and inhibit the replication and development of a broad range of viral pathogens. BSAs work by inhibiting viral proteins (such as polymerases, proteases, or reverse transcriptases) or by targeting host cell proteins and processes exploited by the virus during infection. Many BSAs are found showing efficacy against a given virus outside their original indication, showing antiviral activity against other viruses than originally investigated (such as remdesivir and ritonavir/lopinavir) or outside their original therapeutic indications, for example, antibacterials, like azithromycin, antihelminthics, like niclosamide, and antiprotozoals, like emetine. This makes BSAs potential candidates for drug repurposing.[1] Repurposing of BSAs will allow for quicker, cheaper and more efficient development of antivirals than de novo drug development.
BSAs are potential candidates for treatment of medically important and emerging viruses, such as influenzas, HIV, filoviruses, such as ebola and marburg viruses, and the coronaviruses, SARS-CoV, MERS-CoV and more recently SARS-CoV-2.[1] Efforts in drug repurposing for SARS-CoV-2 is currently underway.
- Broad-spectrum antiviral drugs (BSA) are a class of antiviral drugs, which target and inhibit the replication and development of a broad range of viral pathogens. BSAs work by inhibiting viral proteins (such as polymerases, proteases, or reverse transcriptases) or by targeting host cell proteins and processes exploited by the virus during infection. Many BSAs are found showing efficacy against a given virus outside their original indication, showing antiviral activity against other viruses than originally investigated (such as remdesivir and ritonavir/lopinavir) or outside their original therapeutic indications, for example, antibacterials, like azithromycin, antihelminthics, like niclosamide, and antiprotozoals, like emetine. This makes BSAs potential candidates for drug repurposing.[1] Repurposing of BSAs will allow for quicker, cheaper and more efficient development of antivirals than de novo drug development.
- ↑ 1.0 1.1 García-Serradilla M, Risco C, Pacheco B (April 2019). "Drug repurposing for new, efficient, broad spectrum antivirals". Virus Research. 264: 22–31. doi:10.1016/j.virusres.2019.02.011. PMC 7114681. PMID 30794895.